Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.


This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction

Bramox now available in 10mg strength to aide compliance

Bramox (midodrine hydrochloride), which can be used to treat severe low blood pressure in adults, is now available in 10mg tablets, manufacturer Brancaster Pharma has announced.

Launched yesterday (July 12), the new presentation comes in a colour-coded single tablet, aiding compliance and quality of life in patients who currently have to take two 5mg tablets.

The manufacturer said the newly launched Bramox strength is the only 10mg presentation of midodrine available in the UK and Europe.

Dispensing Bramox 10mg will also give the NHS a cost saving of 10% compared with the price of two 5mg midodrine tablets, the manufacturer claimed.

One 100-tablet pack of Bramox 10mg is listed on the drug tariff for £120.50.

To order, contact AAH, Alliance and Phoenix

For more information, visit the Brancaster Pharma website

Do you dispense many midodrine hydrochloride tablets?

Related Content

Topics

         
Pharmacist Manager
Barnsley
£30 per hour

Apply Now
Latest News & Analysis
See All
UsernamePublicRestriction

Register

CD007281

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel